Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 53 min ago
Peer-reviewedCC BYFrontiers in medicine

Artificial intelligence for ultrasound-based differentiation of soft tissue liposarcoma from benign masses.

  1. 1Department of Medical Ultrasonics, Beijing Jishuitan Hospital Affiliated to Capital Medical University, National Center for Orthopedics, Beijing, China.
  2. 2Department of Vascular Surgery, Beijing Jishuitan Hospital Affiliated to Capital Medical University, National Center for Orthopedics, Beijing, China.

Abstract

Background

Accurate preoperative differentiation of liposarcoma from benign masses on ultrasound remains challenging and operator-dependent. We aimed to develop and validate a deep learning-based model to assist in distinguishing liposarcoma from benign masses.Methods

In this retrospective single-center study, we collected B-mode ultrasound examinations from patients with soft tissue masses between March 2015 and March 2022 at Beijing Jishuitan Hospital affiliated to Capital Medical University. A two-stage deep convolutional neural network was developed: a U-Net model segmented tumor regions, followed by a ResNet50 classifier for tumor type prediction. The cohort (n = 317) was split at the patient level into a development set (n = 222) and an internal test set (n = 95). Model performance was compared with 4 radiologists in the internal test set.Results

Among 317 cases, 191 were benign masses and 126 were liposarcomas. In the internal test set, the AI model achieved an AUC of 0.97 (95% CI 0.92-1.00), an accuracy of 0.97 (95% CI 0.93-1.00), a sensitivity of 0.96 (95% CI 0.86-1.00), and a specificity of 0.97 (95% CI 0.93-1.00). AI achieved significantly higher accuracy than both residents after Holm adjustment (adjusted P = 0.0156 and 0.0352, respectively). Differences between AI and either specialist were not statistically significant (both adjusted P = 1.0000).Conclusions

A two-stage deep learning model using ultrasound images showed preliminary potential for differentiating liposarcoma from benign masses in this single-center cohort. External validation is required before clinical use.

Related

  1. Artificial intelligence-based prostate cancer risk stratification via large-scale ultrasound images paired with histopathology
    Qiong Zhang, Qiang Lu, Yu Liang +3
    Quantitative imaging in medicine and surgeryPeer-reviewedCC BY-NC-NDFull textMedical imaging & radiologyEurope PMC
  2. Validating Artificial Intelligence Guidance for Ultrasound Acquisition and Remote Interpretation
    T. Maldonado, S. Muluk, P. Rali +14
    medRxivPreprintAll rights reservedFull textMedical imaging & radiologymedRxiv
  3. Obstructive 12 cm Esophageal Liposarcoma Removed by Endoscopic Submucosal Dissection and Tissue Fragmentation.
    Tursun Turapov, Abdulrahman Qatomah, John Fang +1
    ACG case reports journalPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  4. Ensuring Safe and Responsible Use of Artificial Intelligence in Medical Imaging: Pitfalls and Practical Solutions through the Lens of Obstetric Ultrasound.
    Rishika Chanian, Ramachandran Thiruvengadam, Bapu Koundinya Desiraju
    The Indian journal of radiology & imagingPeer-reviewedCC BY-NC-NDFull textEpidemiology & public healthEurope PMC
  5. Diagnostic accuracy of tongue diagnosis for stroke syndrome differentiation in traditional Chinese medicine: a systematic review, meta-analysis, and narrative synthesis of artificial intelligence-assisted models.
    Yibo Huang, Jiashun Yin, Siyuan Shao +3
    Frontiers in neurologyPeer-reviewedCC BYFull textNeurologyEurope PMCCrossref
BibTeX
@article{deng2026artificial,
  title = {{Artificial intelligence for ultrasound-based differentiation of soft tissue liposarcoma from benign masses.}},
  author = {YuKun Deng and Chengjia Qu and Yi Cao and Guoyang Yu and Jingmiao Yu and Jie Yang and Wen Guo and Dandan Wang and Xiaoting Qin and Yibing Zhao and Tao Chen},
  journal = {Frontiers in medicine},
  year = {2026},
  month = oct,
  doi = {10.3389/fmed.2026.1960900},
  url = {https://europepmc.org/article/MED/42909320},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Artificial intelligence for ultrasound-based differentiation of soft tissue liposarcoma from benign masses.
AU  - YuKun Deng
AU  - Chengjia Qu
AU  - Yi Cao
AU  - Guoyang Yu
AU  - Jingmiao Yu
AU  - Jie Yang
AU  - Wen Guo
AU  - Dandan Wang
AU  - Xiaoting Qin
AU  - Yibing Zhao
AU  - Tao Chen
PY  - 2026
DA  - 2026/10/07
JO  - Frontiers in medicine
DO  - 10.3389/fmed.2026.1960900
UR  - https://europepmc.org/article/MED/42909320
AB  - Background  Accurate preoperative differentiation of liposarcoma from benign masses on ultrasound remains challenging and operator-dependent. We aimed to develop and validate a deep learning-based model to assist in distinguishing liposarcoma from benign masses.Methods  In this retrospective single-center study, we collected B-mode ultrasound examinations from patients with soft tissue masses between March 2015 and March 2022 at Beijing Jishuitan Hospital affiliated to Capital Medical University. A two-stage deep convolutional neural network was developed: a U-Net model segmented tumor regions, followed by a ResNet50 classifier for tumor type prediction. The cohort (n = 317) was split at the patient level into a development set (n = 222) and an internal test set (n = 95). Model performance was compared with 4 radiologists in the internal test set.Results  Among 317 cases, 191 were benign masses and 126 were liposarcomas. In the internal test set, the AI model achieved an AUC of 0.97 (95% CI 0.92-1.00), an accuracy of 0.97 (95% CI 0.93-1.00), a sensitivity of 0.96 (95% CI 0.86-1.00), and a specificity of 0.97 (95% CI 0.93-1.00). AI achieved significantly higher accuracy than both residents after Holm adjustment (adjusted P = 0.0156 and 0.0352, respectively). Differences between AI and either specialist were not statistically significant (both adjusted P = 1.0000).Conclusions  A two-stage deep learning model using ultrasound images showed preliminary potential for differentiating liposarcoma from benign masses in this single-center cohort. External validation is required before clinical use.
SN  - 2296-858X
ER  -